# EDGAR Filing Document

**Accession Number:** 0001383088
**File Stem:** 0001477932-25-007822
**Filing Date:** 2025-10
**Character Count:** 127216
**Document Hash:** 92ea62910d5f8d061e7ab73d1c63ac90
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-25-007822.hdr.sgml**: 20251031

**ACCESSION NUMBER**: 0001477932-25-007822

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 69

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20251031

**DATE AS OF CHANGE**: 20251030

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYTTA CORP.
- **CENTRAL INDEX KEY:** 0001383088
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 980505761
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-139699
- **FILM NUMBER:** 251437298

**BUSINESS ADDRESS:**
- **STREET 1:** 5450 W SAHARA AVE.
- **STREET 2:** SUITE 300A
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89146
- **BUSINESS PHONE:** 855-511-4426

**MAIL ADDRESS:**
- **STREET 1:** 5450 W SAHARA AVE.
- **STREET 2:** SUITE 300A
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89146

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cytta Corp.
- **DATE OF NAME CHANGE:** 20061208

?xml version='1.0' encoding='ASCII'? cyca_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarter ended: **<u>June 30, 2025</u>**

OR

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Transition Period from ___________ to____________

Commission File Number: **<u>333-257458</u>**

---

| |
|:---|
| **CYTTA CORP.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **98-0505761** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**5450 W Sahara Ave Suite 300A**

**<u>Las Vegas NV 89146</u>**

(Address of principal executive offices) (zip code)

**<u>(702) 900-7022</u>**

(Registrant's telephone number, including area code)

**<u>Not applicable</u>.**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Securities registered pursuant to Section 12(g) of the Act: **Common Stock, $0.001 par value**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated Filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☒ No

As of October 29, 2025, there were 480,237,826 shares outstanding of the registrant's common stock, $0.001 par value per share.

**CYTTA CORP.**

**INDEX**

---

| | | |
|:---|:---|:---|
| **PART I. FINANCIAL INFORMATION** | **PART I. FINANCIAL INFORMATION** |  |
| ITEM 1 | Financial Statements (Unaudited) |  |
|  | [Consolidated Balance Sheets as of June 30, 2025 (unaudited), and September 30, 2024](#BS) | 3 |
|  | [Consolidated Statements of Operations for the three and nine months ended June 30, 2025, and 2024 (Unaudited)](#SO) | 4 |
|  | [Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended June 30, 2025, and 2024 (Unaudited)](#SE) | 5 |
|  | [Consolidated Statements of Cash Flows for the nine months ended June 30, 2025, and 2024 (Unaudited)](#CF) | 7 |
|  | [Notes to Interim Unaudited Consolidated Financial Statements](#NOTES) | 8 |
| [ITEM 2.](#P1I2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#P1I2) | 25 |
| [ITEM 3.](#P1I3) | [Quantitative and Qualitative Disclosures About Market Risk](#P1I3) | 29 |
| [ITEM 4.](#P1I4) | [Controls and Procedures](#P1I4) | 29 |
| **[PART II. OTHER INFORMATION](#P2)** | **[PART II. OTHER INFORMATION](#P2)** |  |
| [ITEM 1.](#P2I1) | [Legal Proceedings](#P2I1) | 30 |
| [ITEM 1A.](#P2I1A) | [Risk Factors](#P2I1A) | 30 |
| [ITEM 2.](#P2I2) | [Unregistered Sales of Equity Securities and Use of Proceeds](#P2I2) | 30 |
| [ITEM 3.](#P2I3) | [Defaults Upon Senior Securities](#P2I3) | 30 |
| [ITEM 4.](#P2I4) | [Mine Safety Disclosures](#P2I4) | 30 |
| [ITEM 5.](#P2I5) | [Other Information](#P2I5) | 30 |
| [ITEM 6.](#P2I6) | [Exhibits](#P2I6) | 31 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#TOC)* |

---

**CYTTA CORP**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **September 30,**<br>**2024** |
| **ASSETS** | (unaudited) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash | $416892 | $1439835 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses- related party | 245763 | 421334 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses- other | 12616 | 122712 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities at fair value | 4747302 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security deposits | 6500 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 5429073 | 1983881 |
| Prepaid expenses, non-current |  | 140443 |
| Property and equipment, net | 24505 | 50867 |
| **TOTAL ASSETS** | $5453578 | $2175191 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $637138 | $524251 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related party liabilities | 432371 | 413093 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend payable | 33427 | 33427 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue |  | 2914 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible notes payable | 305950 | 1438950 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Current Liabilities and Total Liabilities** | 1408886 | 2412635 |
| **COMMITMENTS AND CONTINGENCIES** | - | - |
| **Stockholders' Equity (Deficit)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock par value $0.001; (100,000,000 shares authorized) Series A Preferred Stock par value $0.001; (10,000,000 shares authorized and -0- shares issued and outstanding) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock par value $0.001; (12,000,000 shares authorized and 600,000 shares issued and outstanding) | 600 | 600 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series D Preferred Stock par value $0.001; (10,000,000 shares authorized and 50,000 shares issued and outstanding) | 50 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series E Preferred Stock par value $0.001; (13,650,000 shares authorized and -0- issued and outstanding) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series F Preferred Stock par value $0.001; (59,270,000 shares authorized and -0- issued and outstanding) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock par value $0.001; (600,000,000 shares authorized and 470,237,826 (2025) and 469,877,826 (2024) shares issued and outstanding) | 470239 | 469879 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid in capital | 37073274 | 36159919 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (33499471) | (36867892) |
| Total Stockholders' Equity (Deficit) | 4044692 | (237444) |
| **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)** | $5453578 | $2175191 |

---

The accompanying notes are an integral part of these unaudited financial statements

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#TOC)* |

---

**CYTTA CORP**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended June 30,** | **For the Three Months Ended June 30,** | **For the Nine Months Ended June 30,** | **For the Nine Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenues | $416 | $832 | $2914 | $3243 |
| Cost of revenues | 13194 | - | 50285 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit (Loss) | (12778) | 832 | (47371) | 3243 |
| Operating Expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative - related party | 216860 | 222433 | 659938 | 652475 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative - other | 143330 | 1073314 | 904493 | 2539434 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 360190 | 1295747 | 1564431 | 3191909 |
| Loss from Operations | (372968) | (1294915) | (1611802) | (3188666) |
| Other expenses (income) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 14154 | 159041 | 151900 | 313282 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on settlement of debt |  |  | 787637 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income |  | (179) |  | (502) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on fair value change of marketable securities | 1742138 | - | (5919760) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Expenses (Income) | 1756292 | 158862 | (4980223) | 312780 |
| Income (loss) before income taxes | (2129260) | (1453777) | 3368421 | (3501446) |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | - | - | - | - |
| Net income (loss) | $(2129260) | $(1453777) | $3368421 | $(3501446) |
| Income (Loss) per share, basic | $(0.00) | $(0.00) | $0.01 | $(0.01) |
| Income (Loss) per share, diluted | $(0.00) | $(0.00) | $0.01 | $(0.01) |
| Weighted average shares outstanding, basic | 470237826 | 458786278 | 470083540 | 442623891 |
| Weighted average shares outstanding, diluted | 470237826 | 458786278 | 544222618 | 442623891 |

---

The accompanying notes are an integral part of these unaudited financial statements

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#TOC)* |

---

**CYTTA CORP**

**CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)**

**The Nine Months Ended June 30, 2025**

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series C** | **Series C** | **Series D** | **Series D** |  |  | | | |
|  | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Equity (Deficit)** |
| Balance September 30, 2024 | 600000 | $600 | 50000 | $50 | 469877826 | $469879 | $36159919 | $(36867892) | (237444) |
| Net loss for the three months ended December 31, 2024 | - | - | - | - | - | - | - | (724119) | (724119) |
| Balance December 31, 2024 | 600000 | 600 | 50000 | 50 | 469877826 | 469879 | 36159919 | (37592011) | (961563) |
| Issuance of Reticulate Micro common stock for convertible notes |  |  |  |  |  |  |  |  |  |
| and accrued interest conversion |  |  |  |  |  |  | 905579 |  | 905579 |
| Common stock issued for accounts payable and accrued liabilities |  |  |  |  | 360000 | 360 | 7776 |  | 8136 |
| Net income for the three months ended March 31, 2025 | - | - | - | - | - | - | - | 6221800 | 6221800 |
| Balance March 31, 2025 | 600000 | 600 | 50000 | 50 | 470237826 | 470239 | 37073274 | (31370211) | 6173952 |
| Net loss for the three months ended June 30, 2025 | - | - | - | - | - | - | - | (2129260) | (2129260) |
| Balance June 30, 2025 | 600000 | $600 | 50000 | $50 | 470237826 | $470239 | $37073274 | $(33499471) | $4044692 |

---

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#TOC)* |

---

**CYTTA CORP**

**CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)**

**The Nine Months Ended June 30, 2024**

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series C** | **Series C** | **Series D** | **Series D** |  |  | | | |
|  | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Equity (Deficit)** |
| Balances September 30, 2023 | 600000 | $600 | 50000 | $50 | 426831170 | $426832 | $31915639 | $(32603480) | $(260359) |
| Common stock and warrants issued for services |  |  |  |  | 6000000 | 6000 | 163200 |  | 169200 |
| Common stock issued for accounts payable and accrued liabilities |  |  |  |  | 1887750 | 1888 | 48893 |  | 50781 |
| Net loss for the three months ended December 31, 2023 | - | - | - | - | - | - | - | (1059128) | (1059128) |
| Balance December 31, 2023 | 600000 | 600 | 50000 | 50 | 434718920 | 434720 | 32127732 | (33662608) | (1099506) |
| Common stock issued for services |  |  |  |  | 5000000 | 5000 | 99000 |  | 104000 |
| Common stock issued for accounts payable and accrued liabilities |  |  |  |  | 2227661 | 2228 | 44108 |  | 46336 |
| Warrants vested to purchase common stock |  |  |  |  |  |  | 272299 |  | 272299 |
| Net loss for the three months ended March 31, 2024 | - | - | - | - | - | - | - | (988541) | (988541) |
| Balance March 31, 2024 | 600000 | 600 | 50000 | 50 | 441946581 | 441948 | 32543139 | (34651149) | (1665412) |
| Common stock issued for services |  |  |  |  | 20000000 | 20000 | 501150 |  | 521150 |
| Common stock issued for accounts payable and accrued liabilities |  |  |  |  | 2371687 | 2372 | 66440 |  | 68812 |
| Common stock issued for accounts payable and accrued liabilities, related party |  |  |  |  | 3000000 | 3000 | 87000 |  | 90000 |
| Warrants issued and vested to purchase Reticulate Micro common stock |  |  |  |  |  |  | 119348 |  | 119348 |
| Issuance of Reticulate Micro common stock for convertible note and |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;accrued interest conversion |  |  |  |  |  |  | 2425106 |  | 2425106 |
| Net loss for the three months ended June 30, 2024 | - | - | - | - | - | - | - | (1453777) | (1453777) |
| Balance June 30, 2024 | 600000 | $600 | 50000 | $50 | 467318268 | $467320 | $35742183 | $(36104926) | $105226 |

---

The accompanying notes are an integral part of these unaudited financial statements

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#TOC)* |

---

**CYTTA CORP**

**STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended June 30,** | **For the Nine Months Ended June 30,** |
|  | **2025** | **2024** |
| CASH FLOWS FROM OPERATING ACTIVITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $3368421 | $(3501446) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expenses for services - related party | 365325 | 374751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expenses for services - other | 233606 | 1317126 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on change in fair value of marketable securities | (5919760) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on issuance of RM stock for debt extinguishment | 787637 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of note discounts |  | 46060 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on debt extinguishment | (864) | (14291) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense | 29362 | 31103 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in Operating Assets and Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses - other | (10865) | 76687 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 166656 | 243854 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable-related party | (30047) | 13040 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (2914) | 1752 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security deposits | (6500) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (1019943) | (1411364) |
| CASH FLOWS FROM INVESTING ACTIVITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment | (3000) | (14707) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (3000) | (14707) |
| CASH FLOWS FROM FINANCING ACTIVITIES |  |  |
| Proceeds from issuance of short-term convertible note payable |  | 2468450 |
| Net cash provided by financing activities | - | 2468450 |
| NET CHANGE IN CASH | (1022943) | 1042379 |
| CASH AT BEGINNING OF PERIOD | 1439835 | 674824 |
| CASH AT END OF PERIOD | $416892 | $1717203 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- |
| NON-CASH INVESTING AND FINANCING ACTIVITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for services | $- | $794350 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for accounts payable and accrued liabilities | $8136 | $160251 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for accrued expenses, related party  | $- | $108250 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reticulate Micro common stock issued for convertible notes and accrued interest | $1290400 | $2425106 |

---

The accompanying notes are an integral part of these unaudited financial statements

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#TOC)* |

---

**CYTTA CORP**

**Notes to Financial Statements** 

**June 30, 2025**

**(Unaudited)**

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

Cytta Corp., ("Cytta" or the "Company") was incorporated on May 30, 2006, under the laws of the State of Nevada. It is located in Las Vegas, Nevada. Cytta is in the business of imagineering, developing and securing disruptive technologies.

The Company's proprietary CyttaCOMMS incident management software system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES, is a game-changer in ensuring the safety and well-being of individuals in educational institutions and beyond. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency, even in low bandwidth environments in conjunction with their compression Licensee Reticulate Micro, Inc.

Cytta's proprietary SUPR Intelligence, Surveillance and Reconnaissance (ISR) technology designated CyttaCOMP, is now licensed to Reticulate Micro, Inc. CyttaCOMP, is at the core of our products and is the most potent software compression codec commercially available. CyttaCOMP is explicitly designed for realtime streaming of HD, 4K, and higher resolution video while requiring only limited bandwidth and minimal computational resources.

Cytta's CyttaCOMMS (formerly IGAN<sup>TM</sup> Incident Command System (ICS) system) seamlessly streams and integrates all available video and audio sources during emergencies, enabling sharing of multiple video and audio inputs. The trial (MVP- Minimum Viable Product) version of the CyttaCOMMS product was introduced into the market in the last quarter of 2024. Based upon the information gathered the all of the MVP versions utilizations of the CyttaCOMMS were terminated and the server-side architecture redesigned for an enterprise level sales program when the product is upgraded to incorporate the missing functionality requested. The Company is currently working to finalize the MMP (Minimum Marketable Product) version of the CyttaCOMMS software designated CyttaCOMMS 2.0 for the marketplace.

The CyttaCOMMS online software platform is fully SaaS based with no hardware components. CyttaCOMMS introduces immediate real-time video and audio situational awareness, which is valuable for police, firefighters, first responders, emergency medical workers, industry, environmental and emergencies, security, military, and all their command centers in any emergency. The proprietary IGAN<sup>TM</sup> software technology powers Cytta's SaaS based COMMS system and creates an integrated communications platform which seamlessly streams all available video and audio sources in all critical situations, for first responders enabling real time event and interactive mapping information.

Also based upon the IGAN<sup>TM</sup> technology, Cytta's CyttaCARES (Crisis Alert and Response Emergency System) system is an innovative SAAS solution designed to enhance safety and security in educational institutions, especially during emergency situations. This comprehensive system provides real-time alerts, rapid two-way secure video communication, and efficient response coordination with live location tracking to emergency response teams. The CyttaCARES system has reached the trial or MVP stage, however because of the sensitive nature of the technology the product will require additional work to bring it to the MMP stage, before we begin live school demonstrations.

We have created advanced video compression (SUPR), video/audio streaming and collaboration software (CyttaCOMMS), and school and institution safety and security software systems (CyttaCARES) that solve real world streaming, safety and security problems for multiple institutions and organizations. We believe our products will enable and empower the world to consume higher quality video anywhere, anytime while providing unparallelled safety and security.

On May 13, 2025, the Company formed Cytta Labs Inc (Cytta Labs) as a Wyoming Corporation. Cytta Labs was formed to be a next generation venture studio, and the strategic evolution of Cytta Corp into an innovation holding company focused on IP, equity ownership, and long-term value creation.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#TOC)* |

---

**NOTE 2 - GOING CONCERN**

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2025, the Company had an accumulated deficit of $33,499,471, and limited revenues. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these uncertainties.

The Company intends to fund operations through equity and/or debt financing arrangements, which may not be sufficient to fund its capital expenditures, working capital and other cash requirements for the foreseeable future.

**NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation and consolidation*

The accompanying unaudited consolidated financial statements include the accounts of the Company and Cytta Labs, the Company's wholly owned subsidiary, and have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission ("SEC"). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company's management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2025, and the results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended June 30, 2025, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company's Annual Report on Form 10-K filed on January 14, 2025, for the year ended September 30, 2024. As of June 30, 2025, there has been no activity in Cytta Labs.

*Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

*Reclassifications*

Certain prior period amounts have been reclassified to conform with the current period presentation.

*Cash and Cash Equivalents*

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits of $250,000 per financial institution. The amount in excess of the FDIC insurance as of June 30, 2025, was approximately $167,000. The Company has no cash equivalents at June 30, 2025, and September 30, 2024.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#TOC)* |

---

*Prepaid expenses*

The Company considers expenses or services paid for prior to the period the expense is incurred to be recorded as a prepaid expense. Included in this account is the value of common stock, options and warrants issued to consultants. Such issuances are pursuant to consulting agreements that can have a one-to-three-year term. The Company amortized the value of the stock issued over the term of the agreement. The activity for the nine months ended June 30, 2025, and the year ended September 30, 2024, is summarized as:

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
| Balance beginning of period | $684489 | $1548752 |
| Stock-based compensation |  | 309550 |
| Amortization of stock-based compensation | (436975) | (1093370) |
| Other prepaid expense activity | 10865 | (80443) |
| Sub-total | 258379 | 684489 |
| Less non-current portion (all related party) | - | 140443 |
| Prepaid expenses, current portion | 258379 | 544046 |
| Less prepaid expenses – related party, current portion | 245763 | 421334 |
| Prepaid expenses – other, current portion | $12616 | $122712 |

---

*Marketable Securities at fair value*

Marketable Securities consists of Class A Common Shares of RMX Industries, Inc.(formerly Reticulate Micro, Inc. (RM)) that the Company carries at fair value and are expected to be liquidated within one year from the balance sheet date, are classified as Current Assets.

The Company accounts for marketable and available-for-sale securities under ASU 2016-01, "Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income.

At June 30, 2025, the Company owned 2,434,513 shares and the fair value was reported on the balance sheet as Marketable securities at fair value of $4,747,302 ($1.95/share). The Company recorded $1,742,138 as unrealized loss for the three months ending June 30, 2025, and $5,919,760, as unrealized gain for the nine months ending June 30, 2025, on fair value changes of marketable securities and is included in Other Expenses (Income).

*Property and equipment*

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

---

| | |
|:---|:---|
| Vehicles and equipment | 5 years |
| Software | 3 years |

---

*Convertible Instruments*

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, *Derivatives and Hedging Activities.*

GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not remeasured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#TOC)* |

---

In August 2020, the FASB issued Accounting Standards Update 2020-06 (ASU 2020-06). ASU 2020-06 eliminates the beneficial conversion feature and cash conversion models in Accounting Standards Codification 470-20 that require separate accounting for embedded conversion features in convertible instruments. The new guidance also eliminates some of the conditions that must be met for equity classification under ASC 815-40-25. The standard is effective for smaller reporting companies for annual periods beginning after December 15, 2023. Early adoption is permitted. The Company chose to early adopt this standard. As a result, financial results contained herein are reported in accordance with this standard as applicable.

The convertible debt issued by the Company referred to in Note 7, did not require separate accounting for the conversion feature as it was not considered to be a derivative. The Company issued warrants in connection with the debt financing and in accordance with ASC 470-20-25-2 the proceeds from the sale of the debt instruments have been allocated to the debt and warrants based on the relative fair value of the two components. The amount allocated to the warrants has been recorded as a debt discount to be amortized of the life of the note.

*Fair value of financial instruments*

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

---

| |
|:---|
| Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. |
| Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
| Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. |

---

The carrying amounts of the Company's financial assets and liabilities, such as cash, accounts receivable, accounts payable and accrued expenses, related party liabilities, and deferred revenue, approximate their fair values because of the short maturity of these instruments.

The Company measures the Reticulate Micro common stock it holds at fair value on a recurring basis. The activity for the nine months ended June 30, 2025, is as follows:

---

| | |
|:---|:---|
|  | **June 30,** <br>**2025** |
| Beginning balance | $- |
| Initial value of 2,664,609 RM shares at $3.75 per share | 9992284 |
| Settlement of convertible notes and accrued interest via transfer of 230,095 RM shares | (1172453) |
| Changes in fair value | (4072529) |
| Ending balance June 30, 2025 | $4747302 |

---

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#TOC)* |

---

*Revenue recognition*

Our revenues are primarily generated from fees charged in connection with the implementation of our software platform (including the sale of SaaS products and services, maintenance associated with the sale of on premise software licenses).

Our revenue recognition policy follows the guidance from Accounting Standards Codification ("ASC") 606, "Revenue Recognition," and Accounting Standards Update No. 2014-09 – Revenue from Contracts with Customers (Topic 606) which provide guidance on the recognition, presentation, and disclosure of revenue in financial statements. We determine revenue recognition through the following steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract and (v) recognition of revenue when a performance obligation is satisfied.

Revenue from fees charged in connection with the implementation of our software platform is recognized ratably over the term specified with the customers, which is primarily one year. The transaction price is the amount of consideration to which the Company expects to be entitled to receive in exchange for providing access to its platform. Maintenance and support services generally call for the Company to provide software updates and technical support to customers and is recognized ratably over the term of the contract as this is the period the services are delivered. The Company does not view the provision of initial setup services as a discrete earnings event that is distinct. Our standard payment terms are generally no more than 60 days. SaaS and maintenance services are typically invoiced annually in advance. Amounts billed or collected in excess of revenue recognized are included as deferred revenue.

*Accounts receivable*

The Company records accounts receivable at the time services are invoiced when the access to our platform is delivered or provided to the customers. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

*Stock-based compensation*

The Company accounts for its stock based compensation under the recognition and measurement principles of the fair value recognition provisions of Statement of Financial Accounting Standards No. 123 (revised 2004) "Share-Based Payment" (ASC 718) using the modified prospective method for transactions in which the Company obtains employee services in share-based payment transactions and the Financial Accounting Standards Board Emerging Issues Task Force Issue No. 96-18 "Accounting For Equity Instruments That Are Issued To Other Than Employees For Acquiring, Or In Conjunction With Selling Goods Or Services" ("EITF No. 96-18") for share-based payment transactions with parties other than employees provided in (ASC 718). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the grant date.

*Income taxes*

The Company accounts for income taxes under Statement of Financial Accounting Standards No. 109 "Accounting for Income Taxes" ("SFAS No. 109") (ASC 740). Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#TOC)* |

---

*Cash flows reporting*

The Company follows the provisions of ASC 230 for cash flows reporting and accordingly classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method ("Indirect method") as defined by ASC 230 to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

*Reporting segments*

ASC 280 establishes standards for the way that public enterprises report information about operating segments in annual financial statements and requires reporting of selected information about operating segments in interim financial statements regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performances. Currently, ASC 280 has no effect on the Company's financial statements as substantially all of the Company's operations are conducted in one industry segment.

*Concentrations of Credit Risk*

The Company's financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company's management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

*Earnings (Loss) Per Share of Common Stock*

The Company has adopted ASC 260-10-20, "Earnings per Share," ("EPS") which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.

In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.

To calculate fully diluted earnings per share, the Company uses the Treasury Stock Method. This methodology adds to the Weighted Average Shares Outstanding the number of additional shares that could potentially be issued pursuant to the conversion of all of the Company's in-the-money outstanding convertible securities (including options, warrants and debt), with the further assumptions that all funds (if any) received pursuant to the conversions would be used to purchase the maximum number of shares at the average price per share for the period in order to offset and minimize the dilution effects. Fully Diluted Earnings Per Share is calculated by dividing Net Income by the adjusted Average Weighted Average Shares Outstanding.

The following table represents the classes of dilutive securities as of June 30, 2025, and 2024:

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **June 30,**<br>**2024** |
| Series C Preferred Stock  | 60000000 | 60000000 |
| Series D Preferred Stock  | 50000 | 50000 |
| Convertible notes payable  | 14089078 | 56288838 |
| Unexercised options and warrants  | 24000000 | 28000000 |
| Total | 98139078 | 144388838 |

---

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#TOC)* |

---

The following table represents the basic and diluted weighted average shares outstanding for the three and nine months ended June 30, 2025, and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**June 30,** | **Three months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** |
| **Description** | **2025** | **2024** | **2025** | **2024** |
| Basic weighted average shares outstanding | 470237826 | 458786278 | 470083540 | 442623891 |
| Convertible notes payable |  |  | 14089078 |  |
| Series C Preferred Stock |  |  | 60000000 |  |
| Series D Preferred Stock | - | - | 50000 | - |
| Total | 470237826 | 458786278 | 544222618 | 442623891 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**June 30,** | **Three months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** |
| **Fully Diluted Earnings (loss) per share** | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $(2129260) | $(1453777) | $3368421 | $(3501446) |
| Adjustments | - | - | 41303 | - |
| Adjusted net income (loss) | (2129260) | (1453777) | 3404724 | (3501446) |
| Weighted average number of common shares outstanding | 470237826 | 458786278 | 470083540 | 442623891 |
| Shares computed on if converted basis | - | - | 74139078 | - |
| Total number of shares on fully diluted basis | 470237826 | 458786278 | 544222618 | 442623891 |
| Fully diluted earnings (loss) per share | $(0.00) | $(0.00) | $0.01 | $(0.01) |

---

*Recent Accounting Pronouncements*

There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended June 30, 2025, that are of significance or potential significance to the Company.

**NOTE 4 - PROPERTY AND EQUIPMENT**

The following table represents the Company's property and equipment as of June 30, 2025, and September 30, 2024:

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **September 30,**<br>**2024** |
| Property and equipment | $248606 | $245606 |
| Accumulated depreciation | (224101) | (194739) |
| Property and equipment, net | $24505 | $50867 |

---

Depreciation expense was $9,907 and $29,362 for the three and nine months ended June 30, 2025, respectively, and $10,019 and $31,103 for the three and nine months ended June 30, 2024, respectively.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#TOC)* |

---

**NOTE 5 - RELATED PARTY TRANSACTIONS**

**Related Party agreements and fees**

For the three and nine months ended June 30, 2025, and 2024, the Company recorded expenses to related parties in the following amounts:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**June 30,** | **Three months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** |
| **Description** | **2025** | **2024** | **2025** | **2024** |
| CEO-Management fees | $45000 | $45000 | $135000 | $135000 |
| President and Chief Operating Officer | 45000 | 45000 | 135000 | 135000 |
| Stock-based compensation expense, officers | 118158 | 124708 | 365325 | 374750 |
| Office rent and expenses | 8702 | 7725 | 24613 | 7725 |
| Total | $216860 | $222433 | $659938 | $652475 |

---

Effective January 1, 2023, the monthly fee for the CEO was $15,000.

Effective February 1, 2023, the Company entered a Consulting Executive Officer Agreement with a three- year term to an entity (SGG World LLC or "SGG") to provide the services of a Chief Operating Officer (the "COO") of the Company. On October 1, 2023, the BOD also appointed the COO as the President. Pursuant to the agreement, the Company agreed to a monthly fee of $10,000, and the issuance of 250,000 common shares per month, to be issued semi-annually. The monthly fee was increased to $15,000 per month effective September 1, 2023. For the three months and nine months ended June 30, 2025, the Company recorded expenses of $12,825 and $49,326, respectively, and $19,375 and $58,750, respectively, for the three and nine months ended June 30, 2024, related to the 250,000 common shares per month, calculated based on the closing market price of the common stock on the last day of each month.

The Company granted an option to SGG purchase 10,000,000 shares of the Company's common stock at $0.02 per share with an expiry date of July 1, 2025 (the "CYCA Option"). The CYCA option vests at the rate of 25% beginning on the first six-month anniversary of the agreement, as well as a warrant to purchase 250,000 shares of the Reticulate Micro common stock the Company owns (the "RM Warrant"). The RM Warrant has an exercise price of $1.00 per share and an expiry date of July 1, 2025. The Company valued the CYCA Option at $639,543 based on the Black-Scholes option pricing method and will be amortized through the term of the agreement, and accordingly, $53,295 and $159,885, respectively, is included in stock-based compensation expense-related party for the three and nine months ended June 30, 2025, and 2024, respectively. The Company valued the RM Warrant at $624,458 based on the Black-Scholes option pricing method and will be amortized through the term of the agreement, and accordingly, $52,038 and $156,114, respectively, is included in stock-based compensation expense-related party for the three and nine months ended June 30, 2025, and 2024, respectively.

Beginning in April 2024, the Company agreed to rent office space for the COO at $2,575 per month plus incidental expenses, on a month to month basis, accordingly, $8,703 and $24,613 is included in related party expenses for the three and nine months ended June 30, 2025.

***Related party liabilities***

As of June 30, 2025, and September 30, 2024, the Company owes $432,371 and $413,093, respectively, to related parties as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
| Management fees, Chief Executive Officer (CEO) | $110000 | $110000 |
| Bonus, CEO | 48040 | 68040 |
| Stock to be issued President and COO | 257960 | 208635 |
| Accounts payable, President and COO | 16371 | 26418 |
| Total | $432371 | $413093 |

---

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#TOC)* |

---

**NOTE 6 - CONVERTIBLE NOTES PAYABLE**

During the quarter ended March 31, 2023, (the "March 2023 Notes") the Company issued five (5) convertible promissory notes, in the aggregated principal amount of $160,000, to investors. The notes bear an interest rate of 18% per annum. Principal amount of $100,000 matured on July 1, 2024, and have been extended to July 1, 2025, while principal amount of $60,000 matured on various dates of February 2024 and were all extended to May 31, 2025. Interest payments are due quarterly. The Holders shall have the right to convert all or any part of the outstanding and unpaid principal, interest, and any other amounts due into fully paid and non-assessable shares of common stock of the Company or to the Class A common stock of Reticulate Micro (the "RM Stock") owned by the Company. The notes are convertible into shares of the Company's common stock beginning on the Issuance Date at $0.025, or RM Stock at $1.00 per share. The note proceeds will be used by the Company for general working capital purposes. The Company also agreed to pledge RM stock at $1.00 per share to equal the outstanding principal and interest due upon any defaults of the note. In conjunction with one note of $50,000, the Company issued a warrant to purchase 2,000,000 shares of common stock at an exercise price of $0.025 with an expiration date of July 1, 2025, and a warrant to purchase 100,000 shares of RM Stock at $1.00 per share with an expiry date of July 1, 2025. The warrants issued to purchase the Company's common stock, and the RM Stock resulted in a debt discount of $43,416, with the offset to additional paid in capital. For the three and six months ended March 31, 2024, amortization of the debt discounts of $7,661 and $15,323 was charged to interest expense. In conjunction with one note of $50,000, the Company issued a warrant to purchase 2,000,000 shares of common stock at an exercise price of $0.025 with an expiration date of July 1, 2025, and a warrant to purchase 100,000 shares of RM Stock at $1.00 per share with an expiry date of July 1, 2025. The warrants issued to purchase the Company's common stock, and the RM Stock resulted in a debt discount of $43,585, with the offset to additional paid in capital. For the three and nine months ended June 30, 2024, amortization of the debt discounts of $7,662 and $22,985 was charged to interest expense. Both debt discounts were fully amortized as of September 30, 2024. During the nine months ended June 30, 2025, $10,000 of principal notes and $1,670 of accrued interest were converted into 11,670 shares of RM stock. As of June 30, 2025, and September 30, 2024, the outstanding principal balance of the March 2023 Notes was $150,000 and $160,000, respectively.

During the quarter ended December 31, 2023, (the "December 2023 Notes") the Company issued a convertible promissory note of $40,000, to an investor. The note bears an interest rate of 18% per annum and matured during the quarter ended December 31, 2024, and has been extended to May 31, 2025. Interest payments are due quarterly. The Holder shall have the right to convert all or any part of the outstanding and unpaid principal, interest, and any other amounts due into fully paid and non-assessable shares of common stock of the Company or to the Class A common stock of RM Stock owned by the Company beginning on the Issuance Date of the Company's common stock at $0.025 or RM Stock at $1.00 per share. The note proceeds will be used by the Company for general working capital purposes. The Company also agreed to pledge RM stock at $1.00 per share to equal the outstanding principal and interest due upon any defaults of the note. During the nine months ended June 30, 2025, $40,000 of principal notes and $6,600 of accrued interest were converted into 46,600 shares of RM stock. As of June 30, 2025, and September 30, 2024, there is a balance due of $-0- and $40,000, respectively, on the December 2023 Notes.

During the quarter ended March 31, 2024, (the "March 2024 Notes") the Company issued nine (9) convertible promissory notes in the aggregate of $517,500, to investors. The notes bear an interest rate of 18% per annum and matured during the quarter ended March 31, 2025. Interest payments are due quarterly. The Holder shall have the right to convert all or any part of the outstanding and unpaid principal, interest, and any other amounts due into fully paid and non-assessable shares of common stock of the Company or to the Class A common stock of RM Stock owned by the Company beginning on the Issuance Date of the Company's common stock at $0.025 or RM Stock at $2.00 per share, excluding a note of $250,000 which has a conversion price of $1.00 of RM stock for principal and $2.50 of RM stock for interest. The note proceeds will be used by the Company for general working capital purposes. The Company also agreed to pledge RM stock at $2.00 per share to equal the outstanding principal and interest due upon any defaults of the note. During the year ended September 30, 2024, the lenders of $167,500 of the March 2024 Notes agreed to settle the notes by the issuance of 83,750 shares of RM stock for the principal amount. During the nine months ended June 30, 2025, $350,000 of principal notes and $59,575 of accrued interest were converted into 352,288 shares of RM stock. As of June 30, 2025, and September 30, 2024, there is a balance of $-0- and $350,000, respectively on the March 2024 Notes.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#TOC)* |

---

During the quarter ended June 30, 2024, (the "June 2024 Notes") the Company issued thirty eight (38) convertible promissory notes in the aggregate of $1,910,950 to investors. The notes bear an interest rate of 18% per annum and mature during the quarter ending June 30, 2025. Interest payments are due quarterly. The Holder shall have the right to convert all or any part of the outstanding and unpaid principal, interest, and any other amounts due into fully paid and non-assessable shares of common stock of the Company or to the Class A common stock of RM Stock owned by the Company beginning on the Issuance Date of the Company's common stock at $0.025 or RM Stock at $2.00 per share, excluding $85,000 of June 2024 Notes where the conversion price is $1.00 for the RM stock and $15,000 of June 2024 Notes where the conversion price is $0.025 for the Company's common stock. The note proceeds will be used by the Company for general working capital purposes. The Company also agreed to pledge RM stock at $2.00 per share to equal the outstanding principal and interest due upon any defaults of the note. During the year ended September 30, 2024, the lenders of $1,147,000 of the June 2024 Notes agreed to settle the notes by the issuance of 573,500 shares of RM stock for the principal amount. During the six months ended March 31, 2025, $608,000 of principal notes and $105,395 of accrued interest were converted into 400,648 shares of RM stock. As of June 30, 2025, and September 30, 2024, there is a balance of $155,950 and $763,950, respectively, due on the June 2024 Notes.

During the quarter ended September 30, 2024, (the "September 2024 Notes") the Company issued two (2) convertible promissory notes in the aggregate of $125,000 to investors. The notes bear an interest rate of 18% per annum and mature during the quarter ended September 30, 2025. Interest payments are due quarterly. The Holder shall have the right to convert all or any part of the outstanding and unpaid principal, interest, and any other amounts due into fully paid and non-assessable shares of common stock of the Company or to the Class A common stock of RM Stock owned by the Company beginning on the Issuance Date of the Company's common stock at $0.025 or RM Stock at $2.00 per share. The note proceeds will be used by the Company for general working capital purposes. The Company also agreed to pledge RM stock at $2.00 per share to equal the outstanding principal and interest due upon any defaults of the note. During the nine months ended June 30, 2025, $125,000 of principal notes and $22,500 of accrued interest were converted into 73,750 shares of RM stock. As of June 30, 2025, and September 30, 2024, there is a balance of $-0- and $125,000, respectively, on the September 2024 Notes.

The activity for the nine months ended June 30, 2025, and the year ended September 30, 2024, is summarized as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
| Beginning balance, face value | $1438950 | $1215000 |
| Convertible notes issued |  | 2593450 |
| Convertible notes converted | (1133000) | (2369500) |
| Ending balance | $305950 | $1438950 |

---

The Company has the following convertible notes payable outstanding as of June 30, 2025, and September 30, 2024:

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **September 30,**<br>**2024** |
| March 2023 Convertible notes payable, interest at 18%, $60,000 matured May 31, 2025, and $100,000 matures July 1, 2025 | $150000 | $160000 |
| December 2023 Convertible note payable, interest at 18% |  | 40000 |
| March 2024 Convertible notes payable, interest at 18% |  | 350000 |
| June 2024 Convertible notes payable, interest at 18%, matured during quarter ending June 30, 2025 | 155950 | 763950 |
| September 2024 Convertible notes payable, interest at 18% | - | 125000 |
| Convertible notes payable, balance | $305950 | $1438950 |

---

**NOTE 7 - CAPITAL STOCK** 

*Common Stock*

The Company has authorized 600,000,000 common shares, par value $0.001. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. As of June 30, 2025, and September 30, 2024, there were 470,237,826 and 469,877,826, respectively, common shares issued and outstanding.

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#TOC)* |

---

During the nine months ended June 30, 2025, the following shares of common stock were issued:

· 360,000 shares of common issued for accrued interest, valued at $8,136.

*Preferred Stock*

The Company has 100,000,000 shares authorized as preferred stock, par value $0.001 (the "Preferred Stock"), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

*Series A Preferred Stock*

On March 3, 2025, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company's Series A Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series A Preferred Stock, 10,000,000 shares of the Company's preferred shares are designated as Series A Preferred Stock. Each share of Series A Preferred Stock is convertible into one hundred shares of fully paid and non-assessable Common Stock. For so long as any shares of the Series A Preferred Stock remain issued and outstanding, the Holders thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to one hundred shares for each share of Series A Preferred Stock held. As of June 30, 2025, there were -0- shares of Series A Preferred Stock issued and outstanding.

*Series C Preferred Stock*

Under the terms of the Certificate of Designation of Series C Preferred Stock, 12,000,000 shares of the Company's preferred shares are designated as Series C Preferred Stock. Each share of Series C Preferred Stock is convertible into one hundred shares of Common Stock, and each share of Series C Preferred Stock is entitled to one hundred votes. As of June 30, 2025, and September 30, 2024, there were 600,000 shares of Series C Preferred Stock issued and outstanding.

*Series D Preferred Stock*

On September 30, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company's Series D Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series D Preferred Stock, 10,000,000 shares of the Company's preferred shares are designated as Series D Preferred Stock. Each share of Series D Preferred Stock is convertible into one share of fully paid and non-assessable Common Stock. For so long as any shares of the Series D Preferred Stock remain issued and outstanding, the Holders thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to two times the sum of all the number of shares of other classes of Corporation capital stock eligible to vote on all matters submitted to a vote of the stockholders of the Corporation. As of June 30, 2025, and September 30, 2024, there were 50,000 shares of Series D Preferred Stock issued and outstanding.

*Series E Preferred Stock*

On June 2, 2021, the Company filed a Certificate of Designation with the State of Nevada. Under the terms of the Certificate of Designation 13,650,000 (as amended on June 10, 2021) were designated as Series E Preferred Stock. Each share of Series E Preferred Stock is convertible into one share of fully paid and non-assessable Common Stock. For so long as any shares of the Series E Preferred Stock remain issued and outstanding, the Holders thereof, voting separately as a class, shall have the right to vote one share on all matters submitted to a vote of the stockholders of the Corporation. As of June 30, 2025, and September 30, 2024, there were no shares of Series E Preferred stock issued and outstanding.

*Series F Preferred Stock*

On November 24, 2021, the Company filed a Certificate of Designation with the State of Nevada. Under the terms of the Certificate of Designation 59,270,000 were designated as Series F Preferred Stock. Each share of Series F Preferred Stock is convertible into one share of fully paid and non-assessable Common Stock at any time by the holder. For so long as any shares of the Series F Preferred Stock remain issued and outstanding, the Holders thereof, voting separately as a class, shall have the right to vote one share on all matters submitted to a vote of the stockholders of the Corporation. The Series F Preferred Stock automatically converts to common stock after the shares of common stock closing market price is at least $0.20 for twenty (20) consecutive trading days. As of June 30, 2025, and September 30, 2024, there were no shares of Series F Preferred stock issued and outstanding.

***Stock Options***

The Company did not issue any stock options during the nine months ended June 30, 2025.

On February 1, 2023, pursuant to a three-year consulting agreement, the Company granted an option to SGG (a related party, the representative of which is the Company's COO) to purchase 10,000,000 shares of common stock with an exercise price of $0.02 and an expiration date of July 1, 2025. The options vest over a two-year period at the rate of 25% every six months beginning on the six-month anniversary date of the agreement. The Company valued the option at $639,543 and will amortize the value over the three-year term of the agreement. As of June 30, 2025, 10,000,000 options have vested.

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#TOC)* |

---

On March 3, 2023, pursuant to a one-year consulting agreement, the Company granted an option to a third party to purchase 10,000,000 shares of common stock with an exercise price of $0.02 and an expiration date of July 1, 2025. The options vest over a two-year period at the rate of 25% every six months beginning on the six-month anniversary date of the agreement. The Company valued the option at $449,651 and amortized the value over the one-year term of the agreement. As of June 30, 2025, 10,000,000 options have vested.

The following table summarizes activities related to stock options of the Company for the nine months ended June 30, 2025, and the year ended September 30, 2024.

---

| | | | |
|:---|:---|:---|:---|
|  | **Number of**<br>**Options** | **Weighted-** <br>**Average** <br>**Exercise** <br>**Price**<br>**per Share** | **Weighted-** <br>**Average** <br>**Remaining** <br>**Life (Years)** |
| Outstanding at October 1, 2023 | 20000000 | $0.02 | 1.75 |
| Outstanding at September 30, 2024 | 20000000 | $0.02 | 0.75 |
| Exercisable at September 30, 2024 | 15000000 | $0.02 | - |
| Outstanding at June 30, 2025 | 20000000 | $0.02 | 0.00 |
| Exercisable at June 30, 2025 | 20000000 | $0.02 | - |

---

As of June 30, 2025, and September 30, 2024, -0- and 5,000,000 options to purchase shares of common stock remain unvested and $-0- and $284,241, respectively, of stock compensation expense remains unrecognized and is being expensed over a weighted average period of 2.37 years from the date of the grant.

***Warrants***

On April 1, 2024, pursuant to a consulting agreement, the Company issued a warrant to a third party to purchase 50,000 shares of RM Stock that vested immediately and with an exercise price of $1.50 and an expiration date of April 1, 2025. The Company valued the warrant at $119,348 based on the Black Scholes option pricing model and expensed when granted. The following assumptions were utilized in the Black-Scholes valuation of this immediately vested warrant during the year ended September 30, 2024, risk free interest rate of 5.03%, volatility of 145% and an exercise price of $1.50.

On February 1, 2023, pursuant to a three-year consulting agreement, the Company granted a warrant to a related party (SGG) to purchase 250,000 shares of RM common stock with an exercise price of $1.00 and an expiration date of July 1, 2025. The Company valued the warrant at $624,458 and will amortize the value over the three-year term of the agreement. For the three and nine months ended June 30, 2025, and 2024, the Company has included $52,038 and $156,114 in stock-based compensation expense-related party, respectively.

On February 8, 2023, an investor paid $5,000 to acquire a warrant to purchase 2,000,000 shares of common stock. The warrant has an exercise price of $0.02 per share and expires July 1, 2024. The Company also issued a warrant to purchase 100,000 shares of RM Stock, with an exercise price of $1.00 and an expiration date of July 1, 2025, as amended.

On February 10, 2023, pursuant to a convertible note with a current shareholder of the Company, the Company issued a warrant to the investor to purchase 2,000,000 shares of common stock at an exercise price of $0.025 per share and an expiration date of July 1, 2025. The Company valued the warrant at $79,914, based on the Black Scholes option pricing model. The Company also issued a warrant to purchase 100,000 shares of RM Stock at an exercise price of $1.00 and an expiration date of July 1, 2025. The Company valued the RM Stock warrant at $249,811, based on the Black Scholes option pricing model. The Company applied $43,416 to the note as a discount based on the allocations of the fair values of the warrants and the note. The Company charged the note discount to interest expense over the term of the note. For the three and nine months ended June 30, 2024, the Company recorded interest expense of $7,662 and $22,985, respectively. The note discount was fully amortized as of September 30, 2024.

---

| |
|:---|
| 19 |
| *[**Table of Contents**](#TOC)* |

---

On March 1, 2023, an investor paid $5,000 to acquire a warrant to purchase 2,000,000 shares of common stock. The warrant has an exercise price of $0.02 per share and expires July 1, 2024. The Company also issued a warrant to purchase 100,000 shares of RM Stock, with an exercise price of $1.00 and an expiration date of July 1, 2025, as amended.

On March 3, 2023, pursuant to a convertible note with a current shareholder of the Company, the Company issued a warrant to the investor to purchase 2,000,000 shares of common stock at an exercise price of $0.025 per share and an expiration date of July 1, 2025. The Company valued the warrant at $89,916, based on the Black Scholes option pricing model. The Company also issued a warrant to purchase 100,000 shares of RM Stock at an exercise price of $1.00 and an expiration date of July 1, 2025. The Company valued the RM Stock warrant at $249,822, based on the Black Scholes option pricing model. The Company applied $43,585 to the note as a discount based on the allocations of the fair values of the warrants and the note. The Company charged the note discount to interest expense over the term of the note. For the three and nine months ended June 30, 2024, the Company recorded interest expenses of $7,692 and $23,075, respectively. The note discount was fully amortized as of September 30, 2024.

On March 3, 2023, pursuant to a one-year consulting agreement with a Company shareholder, the Company issued to the shareholder a warrant to purchase 250,000 shares of RM Stock with an exercise price of $1.00 and an expiration date of July 1, 2025. The Company valued the warrant at $624,556 and amortized the value over the one-year term of the agreement. For the three and nine months ended June 30, 2024, the Company has included $-0- and $260,232, respectively, in general and administrative expenses. The warrant value was fully amortized as of September 30, 2024.

The following table summarizes activities related to warrants of the Company for the nine months ended June 30, 2025, and the year ended September 30, 2024.

---

| | | | |
|:---|:---|:---|:---|
|  | **Number of** <br>**Warrants** | **Weighted** <br>**Average** <br>**Exercise** <br>**Price** <br>**Per Share** | **Weighted** <br>**Average** <br>**Remining** <br>**Life (Years)** |
| Outstanding and exercisable at October 1, 2023 | 8000000 | $0.0225 | 1.25 |
| Expired or cancelled or forfeited | (4000000) | 0.0200 | - |
| Outstanding and exercisable at September 30, 2024 | 4000000 | $0.0250 | 0.75 |
| Outstanding and exercisable at June 30, 2025 | 4000000 | $0.0250 | 0.00 |

---

The following table summarizes activities related to warrants to purchase RM Stock from the Company for nine months ended June 30, 2025, and the year ended September 30, 2024.

---

| | | | |
|:---|:---|:---|:---|
|  | **Number of** <br>**Warrants** | **Weighted** <br>**Average** <br>**Exercise** <br>**Price** <br>**Per Share** | **Weighted** <br>**Average** <br>**Remining** <br>**Life (Years)** |
| Outstanding and exercisable at October 1, 2023 | 900000 | $1.00 | 1.53 |
| Issued  | 50000 | 1.50 | 1.00 |
| Outstanding and exercisable at September 30, 2024 | 950000 | $1.03 | 0.74 |
| Outstanding and exercisable at June 30, 2025 | 950000 | $1.03 | 0.00 |

---

---

| |
|:---|
| 20 |
| *[**Table of Contents**](#TOC)* |

---

**NOTE 8 - COMMITMENTS AND CONTINGENCIES**

The Company does not have an existing contract with the CEO. The monthly compensation and any bonus amounts are at the discretion of the Board of Directors. Effective January 1, 2023, the Company agreed to compensate the CEO $15,000 per month.

Effective February 1, 2023, the Company entered a Consulting Executive Officer Agreement with a three- year term to an entity (SGG) to provide the services of a Chief Operating Officer (the "COO") of the Company. On October 1, 2023, the BOD also appointed the COO as the President. Pursuant to the agreement, the Company agreed to a monthly fee of $10,000, and the issuance of 250,000 common shares per month, to be issued semi-annually. The monthly fee was increased to $15,000 per month effective September 1, 2023. For the three and nine months ended June 30, 2025, the Company recorded expenses of $12,825 and $49,326, respectively, and $19,375 and $58,751, respectively, for the three and nine months ended June 30, 2024, related to the 250,000 common shares per month, calculated based on the closing market price of the common stock on the last day of each month.

On May 8, 2024, the Company issued 3,000,000 shares of common stock for the months of February 2023, through January 2024. On May 11, 2023, the Company issued 5,000,000 shares to the Company's COO as a bonus pursuant to their Consulting Agreement. On July 10, 2023, the Company issued 15,000,000 shares to the Company's COO as a bonus pursuant to their Consulting Agreement. On September 7, 2023, the Company issued 5,000,000 shares to the Company's COO as a bonus pursuant to their Consulting Agreement.

Additionally, the Company granted an option to SGG, a related party (the representative of which is the Company's COO), to purchase 10,000,000 shares of the Company's common stock at $0.02 per share with an expiry date of July 1, 2025 (the "CYCA Option"). The CYCA option vests at the rate of 25% beginning on the first six-month anniversary of the agreement, as well as a warrant to purchase 250,000 shares of the Reticulate Micro common stock the Company owns (the "RM Warrant"). The RM Warrant has an exercise price of $1.00 per share and an expiry date of July 1, 2025. The Company valued the CYCA Option at $639,543 based on the Black-Scholes option pricing method and will be amortized through the term of the agreement, and accordingly, $53,295 and $159,885, respectively, is included in stock-based compensation expense-related party for the three and nine months ended June 30, 2025, and 2024, respectively. The Company valued the RM Warrant at $624,458 based on the Black-Scholes option pricing method and will be amortized through the term of the agreement, and accordingly, $52,038 and $156,114, respectively, is included in stock-based compensation expense-related party for the three and nine months ended June 30, 2025, and 2024, respectively.

On March 3, 2023, the Company entered a Consulting Agreement with an investor. Pursuant to the agreement, the Company issued 2,000,000 shares of common stock for one year of services. The Company valued the shares at $80,000 based on the price of the common stock on the date the Company agreed to issue the common stock. The Company also issued the consultant 1) an option to purchase 10,000,000 shares of the Company's common stock at an exercise price of $0.02 per share with an expiry date of July 1, 2025. The options vest over the two-year period in 25% increments beginning on the six- month anniversary of the agreement and 2) a warrant to purchase 250,000 shares of RM Stock at an exercise price of $1.00 per share with an expiry date of July 1, 2025. The option to purchase the Company's common stock was valued at $449,651 based on the Black Scholes option pricing model and was amortized over the one-year term of the agreement. For the three and nine months ended June 30, 2024, $74,942, and $187,355 is included in stock-based compensation expense, respectively, and this option value was fully amortized as of September 30, 2024. The warrant to purchase the RM Stock was valued at $624,556 based on the Black Scholes option pricing model and was amortized over the one-year term of the agreement. For the three and nine months ended June 30, 2024, $-0- and $260,232 is included in stock-based compensation expense, respectively. and this warrant value was fully amortized as of September 30, 2024. On December 6, 2023, the Company agreed to issue an additional 6,000,000 shares of common stock. The Company valued the 6,000,000 shares at $0.0282 per share and included stock-based compensation expense of $169,200 for the nine months ended June 30, 2024. On May 16, 2024, the Company agreed to issue an additional 2,500,000 shares of common stock. The Company valued the 2,500,000 shares at $0.03 per share and included stock-based compensation expense of $75,000 for the three and nine months ended June 30, 2024.

On April 1, 2023, the Company entered a Consulting Agreement with a third party for marketing services in exchange for 250,000 shares of restricted common stock. The shares vest in 12 equal amounts of 20,833. For the three and nine months ended June 30, 2024, the Company has recorded stock-based compensation of $-0- and $6,012, respectively, with the offset to accounts payable and accrued expenses.

---

| |
|:---|
| 21 |
| *[**Table of Contents**](#TOC)* |

---

On October 1, 2023, the Company entered into a one-year Agreement for Board of Advisor Services with a third party to provide general technical, AI, sales, and marketing services in exchange for 3,000,000 shares of common stock. The Company valued the shares at $80,700 ($0.0269 per share). The shares are to be issued at the end of the term, and the Company is amortizing the expense over the term of the contract. For the three and nine months ended June 30, 2024, the Company included $20,175 and $60,525, respectively, in General and Administrative expenses and in accounts payable and accrued expenses. Effective May 1, 2024, the Company amended the October 1, 2023, agreement and agreed to issue 7,000,000 shares, of which 5,000,000 were immediately earned and were issued May 16, 2024, and to issue an additional 2,000,000 shares at the end of the term. The Company valued and expensed the 5,000,000 shares at $142,500 ($0.0285 per share) on the date of the agreement, and the Company is amortizing the expense related to the 2,000,000 shares (valued at $57,000) over the term of the contract. For the three and nine months ended June 30, 2025, the Company included $4,750 and $33,250 in General and Administrative expenses and $57,000 in accounts payable and accrued expenses.

On January 1, 2024, the Company entered into a one-year Consulting Agreement with a third party to provide market awareness services and the identification, evaluation, structuring, negotiating, and closing of joint ventures, strategic alliances, and business acquisitions, in exchange for 3,000,000 shares of common stock. The Company valued the shares at $62,400 and is amortizing the expense over the term of the contract. For the nine months ended June 30, 2025, the Company included $15,600 in General and Administrative expenses.

On January 2, 2024, the Company entered into a one-year Consulting Agreement with a third party to provide market awareness services and the identification, evaluation, structuring, negotiating, and closing of joint ventures, strategic alliances, and business acquisitions, in exchange for a monthly fee of $10,000 per month and 5,000,000 shares of common stock. The shares were issued on January 18, 2024. The Company valued the shares at $104,000 and is amortizing the expense over the term of the contract. For the nine months ended June 30, 2025, the Company included $26,000 in General and Administrative expenses.

On April 1, 2024, the Company entered an Agreement for Board of Advisor Services with a third party to provide general business, military, governmental, technical, AI, and sales and marketing services, in exchange for 2,500,000 shares of common stock upon execution of the agreement (the "Initial Issuance") and a further 2,500,000 shares of common stock one year after the execution (the "Final Issuance"). The Initial Issuance of 2,500,000 shares of common stock were issued on May 8, 2024. The Company valued the 5,000,000 shares at $137,500 among which $68,750 related to Initial Issuance and is amortizing over the term of the contract. For the nine months ended June 30, 2025, the Company included $68,750 in General and Administrative expenses, including the amortization of prepaid expenses of $34,375 (Initial Issuance) and $34,375 accrued in accounts payable and accrued expenses (Final Issuance). In connection with the agreement, the Company also agreed to issue a warrant to purchase 50,000 Class A common stock shares of RM Stock owned by the Company, at $1.50 per share and vested immediately. The warrant to purchase the RM Stock was valued at $119,348 based on the Black Scholes option pricing model and was expensed when granted.

On April 23, 2024, the Company entered an Agreement for Board of Advisor Services with a third party to provide assistance to the Company in building its in house development team and manage software projects, in exchange for 3,000,000 shares of common stock. The Company issued 1,500,000 shares of common stock on May 8, 2024, with the balance due on the one-year anniversary of the agreement. The Company valued the 3,000,000 shares at $67,500 among which $33,750 related to the already issued common shares and is amortizing over the term of the contract. For the nine months ended June 30, 2025, the Company included $33,750 in General and Administrative expenses, including the amortization of prepaid expenses of $16,875 and $16,875 accrued in accounts payable and accrued expenses.

On April 23, 2024, the Company entered an Agreement for Board of Advisor Services with a third party to provide general business, military, governmental, technical, AI, and sales and marketing services, in exchange for 5,000,000 shares of common stock. The Company issued 2,500,000 shares of common stock on May 8, 2024, with the balance due on the one-year anniversary of the agreement. The Company valued the 5,000,000 shares at $112,500 among which $56,250 relates to the already issued common shares and is amortizing over the term of the contract. For the nine months ended June 30, 2025, the Company included $56,250 in General and Administrative expenses, including the amortization of prepaid expenses of $28,125 and $28,125 accrued in accounts payable and accrued expenses.

---

| |
|:---|
| 22 |
| *[**Table of Contents**](#TOC)* |

---

**NOTE 9 - LICENSE AGREEMENT**

On August 9, 2022, the Company signed an Intellectual Property License Agreement (the "IPLA") with Reticulate Micro, Inc. ("RM"). Pursuant to the ten-year term (the "Term") of IPLA, RM agreed to issue to the Company 5,100,000 shares of RM's Class A Common Stock and a royalty of 5% of net sales during the Term in exchange for the licensing of the Company's technology related to its SUPR ISR (the Superior Utilization of Processing Resources- Intelligence, Surveillance and Reconnaissance).

RM, a Nevada corporation, was formed on June 22, 2022. Mr. Collins, the Company's' former CTO was a co-founder, and a former Director and President and Treasurer of RM. Mr. Chermak, the Company's former COO is a co-founder, Director and Vice-president and Secretary of RM. Mr. Ansari is a co-founder and former Director of RM. RM had initially issued 1,600,000, 1,000,000 and 1,000,000 shares of Class B Common Stock to Mr. Collins. Mr. Chermak and Mr. Ansari, respectively. On May 15, 2023, Mr. Collins cancelled his 1,600,000 shares of Class B common stock in exchange for 200,000 shares of Class A common stock. As of June 30, 2025, and September 30, 2024, RM has 2,000,000 and 2,000,000 Class B Common Stock shares are outstanding, respectively. Each share of the Class B Common Stock has voting rights whereby each share of Class B Common Stock equals 100 voting shares. As of June 30, 2025, and September 30, 2024, RM had 19,778,946 and 10,459,199 Class A common stock shares issued and outstanding, respectively. As of June 30, 2025, the Company has issued 2,620,486 shares of RM stock in satisfaction of $3,502,500 of principal of convertible notes and $280,627 of accrued interest. The Company also issued 45,000 shares of RM stock in satisfaction of note payable (principal and interest). Accordingly, as of June 30, 2025, and September 30, 2024, the Company's 2,434,514 and 3,319,469 shares, respectively, of RM Class A Common Stock represents approximately 1.11% and 1.57%, respectively of the voting stock of RM. Each share of the Class B Common stock is also convertible into one share of Class A Common Stock.

The Company initially accounted for its interest in RM under the cost method of accounting. On January 30, 2025, the Company pursuant to ASC 321 was able to identify observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Accordingly, Company began to measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. A separate election to use the alternative needs to be made for each eligible investment and the alternative should be applied consistently from period to period until the investment's fair value becomes readily determinable. Entities are also required to reassess at each reporting period whether an investment qualifies for the alternative.

From January 1, 2025, through January 29, 2025, the Company issued 654,860 shares of RM stock in settlement of $803,000 of principal and $138,175 of accrued interest on convertible notes. On January 30, 2025, the Company recorded the initial fair value of the 2,664,609 shares at $9,992,284 the initial value) to marketable securities at fair value, based on $3.75 per share (the opening price of RM on OTC Markets with the offset to unrealized gain on marketable securities). From January 30, 2025, through June 30, 2025, the Company issued 230,095 shares of RM Class A Common Stock in settlement of $330,000 of principal and $54,820 of accrued interest on convertible notes and recorded a loss on the issuances of the shares of $787,637 which is included in loss on settlement of debt in other income (expense), in its Statements of Operations for the nine months ended June 30, 2025. The Company also recorded a net unrealized loss of $1,742,138 and a net unrealized gain of $5,919,760 for the three and nine months ended June 30, 2025, respectively, based on the changes in fair value during the three and nine months ended June 30, 2025. As of June 30, 2025, the marketable securities at fair value are $4,747,302 and are included in current assets on the balance sheet.

**NOTE 10 - INCOME TAXES**

The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

---

| |
|:---|
| 23 |
| *[**Table of Contents**](#TOC)* |

---

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future income, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, there is a full valuation allowance provided against the Company's deferred tax assets as of June 30, 2025, and September 30, 2024.

A reconciliation of the provision for income taxes determined at the U.S. statutory rate to the Company's effective income tax rate is as follows:

---

| | | |
|:---|:---|:---|
|  | **Nine months** <br>**ended** <br>**June 30, 2025** | **Nine months** <br>**Ended** <br>**June 30, 2024** |
| Pre-tax income (loss) | $3368421 | $(3501466) |
| U.S. federal corporate income tax rate | 21% | 21% |
| Expected U.S. income tax (credit) | 707368 | (735308) |
| Permanent differences | (1117374) | 355294 |
| Change of valuation allowance | 410006 | 380014 |
| Effective tax expense | $— | $— |

---

The Company had deferred tax assets as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
| Net operating losses carried forward | $2855356 | $2353239 |
| Less: Valuation allowance | (2855356) | (2353239) |
| Net deferred tax assets | $— | $— |

---

As of June 30, 2025, and September 30, 2024, the Company has approximately $13,596,000 and $11,645,000, respectively, net operating loss carryforwards available to reduce future taxable income. As of June 30, 2025, and September 30, 2024, the Company has no material unrecognized tax benefits which would favorably affect the effective income tax rate in future periods and does not believe that there will be any significant increases or decreases of unrecognized tax benefits within the next twelve months. No interest or penalties relating to income tax matters have been imposed on the Company during the three and nine months ended June 30, 2025, and 2024, and no provision for interest and penalties is deemed necessary as of June 30, 2025, and September 30, 2024.

**NOTE 11 - DEFERRED REVENUE**

The Company records the agreed amounts over the one-year term of the subscription agreements as deferred revenue, classified as a liability on the balance sheet, and amortizes the deferred revenue over the subscription period. For the three and nine months ended June 30, 2025, the Company recognized $416 and $2,914, respectively, compared to $832 and $3,243 for the three and nine months ended June 30, 2024, respectively, of revenue from these agreements. As of June 30, 2025, there is no deferred revenue.

**NOTE 12 - SUBSEQUENT EVENTS**

On August 27, 2025, the Company transferred 100,000 shares of RM stock in satisfaction of $100,000 of principal of convertible notes.

From September 8, 2024, through October 28, 2025, the Company sold 822,337 shares of the RM stock it owned for $625,500.

On October 14, 2025, the Company agreed to transfer, and 2 individuals agreed to accept 150,000 shares of RM stock in the aggregate, in satisfaction of shares of Company common stock the Company owed to the individuals.

On October 15, 2025, the Company issued 10,000,000 shares of common stock, valued at $220,000 ($0.022 per share, the market price on the date of the agreement) to an existing shareholder, pursuant to a consulting agreement.

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements.

---

| |
|:---|
| 24 |
| *[**Table of Contents**](#TOC)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following is management's discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words "believes," "anticipates," "may," "will," "should," "expect," "intend," "estimate," "continue," and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward -looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates.

The following discussion should be read in conjunction with our unaudited financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q.

**THE COMPANY**

Cytta Corp., ("Cytta" or the "Company") was incorporated on May 30, 2006, under the laws of the State of Nevada. It is located in Las Vegas, Nevada. Cytta is in the business of imagineering, developing and securing disruptive technologies.

**Results of Operations for the three and nine months ended June 30, 2025, and 2024:**

Revenues for the three and nine months ended June 30, 2025, were $416 and $2,914, respectively, compared to $832 and $3,243, respectively, for the three and nine months ended June 30, 2024, and were from deferred revenue on subscription agreements being recognized.

Revenues consist of our proprietary software, integration consulting services, tech support and product maintenance billed to the customer.

Cost of sales for the three and nine months ended June 30, 2025, were $13,195 and $50,285, respectively, and consisted of hosting fees. There was no hosting fees for cost of sales for the three and nine months ended June 30, 2024.

---

| |
|:---|
| 25 |
| *[**Table of Contents**](#TOC)* |

---

Operating expenses were $360,190 and $1,564,431 for the three and nine months ended June 30, 2025, compared to $1,295,747 and $3,191,909 for the three and nine months ended June 30, 2024. The decreases of $935,557 and $1,627,478 for the three and nine months ended June 30, 2025, compared to the three and nine months ended June 30, 2024, are as shown in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**June 30,** | **Three months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** |
| **Description** | **2025** | **2024** | **2025** | **2024** |
| Related party expenses (excluding stock-based compensation) | $98703 | $97725 | $294613 | $277725 |
| Stock based compensation | 4750 | 575127 | 233606 | 1317127 |
| Stock based compensation, officers | 118158 | 124708 | 365325 | 374750 |
| Professional fees | 46000 | 51460 | 167349 | 157961 |
| Consulting expenses (excluding stock-based compensation) | 9575 | 237375 | 9575 | 459375 |
| Depreciation expense | 9907 | 10019 | 29362 | 31103 |
| Software and demo expenses | 835 | 743 | 18529 | 188203 |
| General and Administrative, officers | 10525 | 3798 | 18215 | 9603 |
| Auto, travel and entertainment | 9987 | 13855 | 28747 | 35744 |
| Rent expense | 11250 | 6748 | 33873 | 19930 |
| Transfer agent and filing fees | 7909 | 11255 | 22369 | 27865 |
| Investor relations | 2247 | 147520 | 250914 | 237001 |
| Gain on debt extinguishment |  | (9457) | (864) | (14291) |
| Other operating expenses | 30343 | 24871 | 92818 | 69813 |
| Total | $360190 | $1295747 | $1564431 | $3191909 |

---

Related party expenses (excluding stock expenses) increased for the three and nine months ended June 30, 2025, compared to the three and nine months ended June 30, 2024, as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**June 30,** | **Three months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** |
| **Description** | **2025** | **2024** | **2025** | **2024** |
| Management fees, Chief Executive Officer (CEO) | $45000 | $45000 | $135000 | $135000 |
| Management fees, Chief Operation Officer (COO) | 45000 | 45000 | 135000 | 135000 |
| Office rent and expenses | 8703 | 7725 | 24613 | 7725 |
| Total | $98703 | $97725 | $294613 | $277725 |

---

Effective January 1, 2023, the monthly fee for the CEO was $15,000 and effective September 1, 2023, the monthly fee for the President and COO was $15,000. Beginning in April 2024, the Company agreed to rent office space for the COO at $2,575 per month plus incidental expenses, on a month to month basis, accordingly, $8,703 and $24,613 is included in related party expenses for the three and nine months ended June 30, 2025, respectively, and $7,725 is included in related party expenses for the three and nine months ended June 30, 2024.

Stock-based compensation expenses decreased in the current periods compared to the prior periods. For the three and nine months ended June 30, 2025, stock-based expenses include the compensation of $4,750 and $233,606 related to common stock all previously issued (amortization of prepaids) or to be issued (accrued), pursuant to the terms of each consultant's contracts. For the three and nine months ended June 30, 2024, stock-based expenses , were related to shares issued to consultants of $300,000 and $469,200, respectively and the amortization of common stock (pursuant to the terms of each consultant's contracts), options and warrants of $275,127 and $847,927 respectively.

Stock based compensation - officers was comprised pursuant to the agreement with the COO (SGG) to issue 250,000 common shares per month. For the three and nine months ended June 30, 2025, the Company recorded expenses of $12,825 and $49,325, respectively. For the three and nine months ended June 30, 2024, the Company recorded an expense of $19,375 and $58,750 related to the 250,000 shares per month. Additionally, the Company granted an option to SGG (a related party) to purchase 10,000,000 shares of the Company's common stock at $0.02 per share with an expiry date of July 1, 2025 (the "CYCA Option"). The CYCA option vests at the rate of 25% beginning on the first six-month anniversary of the agreement, as well as a warrant to purchase 250,000 shares of the Reticulate Micro common stock the Company owns (the "RM Warrant"). The RM Warrant has an exercise price of $1.00 per share and an expiry date of July 1, 2025. The Company valued the CYCA Option at $639,543 based on the Black-Scholes option pricing method and will be amortized through the term of the agreement, and accordingly, $53,295 and $159,885, is included in stock-based compensation expense-related party for the three and nine months ended June 30, 2025, and 2024, respectively. The Company valued the RM Warrant at $624,458 based on the Black-Scholes option pricing method and will be amortized through the term of the agreement, and accordingly, $52,038 and $156,114 is included in stock-based compensation expense-related party for the three and nine months ended June 30, 2025, and 2024, respectively.

---

| |
|:---|
| 26 |
| *[**Table of Contents**](#TOC)* |

---

Professional fees remained fairly constant for the three and nine months ended June 30, 2025, compared to the three and nine months ended June 30, 2024.

Consulting expenses (excluding stock expenses) decreased during the three and nine months ended June 30, 2025, compared to the three and nine months ended June 30, 2024, as certain consultants engaged in the prior periods were not engaged in the current periods.

Investor relations fees decreased for the three and increased for the nine months ended June 30, 2025, compared to the three and nine months ended June 30, 2024. The current three month decrease was the termination with cause of the investor relation firm.

For the three months ended June 30, 2025, other expenses were $1,756,292, compared to $158,862 for the three months ended June 30, 2024. The increase was a result of the unrealized loss on the change in fair value of the RM common stock (marketable securities). For the nine months ended June 30, 2025, other income was $4,980,223 compared to other expense of $312,780 for the nine months ended June 30, 2024. For the nine months ended June 30, 2025, other income of $4,980,223, was the result of the $5,919,760 unrealized gain on the fair value change of the RM common stock, partially offset by the loss on settlement of debt.

Interest expense decreased for the three and nine months ended June 30, 2025, compared to the three and nine months ended June 30, 2024, due to settlements of notes payable.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**June 30,** | **Three months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** | **Nine months ended** <br>**June 30,** |
| **Description** | **2025** | **2024** | **2025** | **2024** |
| Interest expense | $14154 | $159041 | $151900 | $313282 |
| Loss on RM shares issued for debt conversions |  |  | 787637 |  |
| Unrealized gain on fair value change of marketable securities | 1742138 |  | (5919760) |  |
| Interest income | - | (179) | - | (502) |
| Total Other Expense (Income) | $1756292 | $158862 | $(4980223) | $312780 |

---

The following tables set forth key components of our balance sheet as of June 30, 2025, and September 30, 2024.

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **September 30,**<br>**2024** |
| Current Assets | $5429073 | $1983881 |
| Long term assets | $24505 | $191310 |
| Total Assets | $5453578 | $2175191 |
| Current and Total Liabilities | $1408886 | $2412635 |
| Stockholders' Equity (Deficit) | $4044692 | $(237444) |
| Total Liabilities and Stockholders' Equity (Deficit) | $5453578 | $2175191 |

---

---

| |
|:---|
| 27 |
| *[**Table of Contents**](#TOC)* |

---

**Liquidity and Capital Resources**

As of June 30, 2025, we had limited operating capital. Our current capital and our other existing resources will not be sufficient to provide the working capital needed for our current business. Additional capital will be required to meet our obligations, and to further expand our business. We may be unable to obtain the additional capital required. Our inability to generate capital or raise additional funds when required will have a negative impact on our business development and financial results. These conditions raise substantial doubt about our ability to continue as a going concern as well as our recurring losses from operations and the need to raise additional capital to fund operations. This "going concern" could impair our ability to finance our operations through the sale of debt or equity securities.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2025, the Company had an accumulated deficit of $33,499,472 and limited revenue. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these uncertainties. The Company intends to fund operations through equity and/or debt financing arrangements, which may not be sufficient to fund its capital expenditures, working capital and other cash requirements for the foreseeable future.

As of June 30, 2025, we had cash of $416,892 compared to $1,439,835 at September 30, 2024. As of June 30, 2025, we had current assets of $5,429,073 and current liabilities of $1,408,886, which resulted in working capital of $4,020,187. The current liabilities are comprised of accounts payable and accrued expenses, related party liabilities, dividend payable and convertible notes payable.

*Operating Activities*

For the nine months ended June 30, 2025, net cash used in operating activities was $1,019,943 compared to $1,411,364 for the nine months ended June 30, 2024. For the nine months ended June 30, 2025, our net cash used in operating activities was primarily attributable to net income of $3,368,421, adjusted by the unrealized gain on the fair value change of marketable securities of $5,919,760, the loss on issuance of RM stock in settlement of debt conversions of $787,637, stock-based compensation of $608,931, and depreciation of $29,362. Net changes of $106,330 in operating assets and liabilities decreased the cash used in operating activities.

For the nine months ended June 30, 2024, our net cash used in operating activities was primarily attributable to the net loss of $3,501,446 adjusted by stock-based compensation of $1,691,877, amortization of note discounts of $46,060, gain on debt extinguishment of $14,291 and amortization and depreciation of $31,103. Net changes of $335,333 in operating assets and liabilities decreased the cash used in operating activities.

*Investing Activities*

For the nine months ended June 30, 2025, the Company purchased $3,000 of property and equipment. For the nine months ended June 30, 2024, the Company spent $14,707 for the purchase of property and equipment.

*Financing Activities*

For the nine months ended June 30, 2025, there were no financing activities.

For the nine months ended June 30, 2024, the Company received $2,468,450 in exchange for the issuance of various convertible promissory notes.

**Critical Accounting Policies**

Our significant accounting policies are summarized in Note 3 of our financial statements. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. The SEC requested that all registrants list their most "critical accounting polices" in the Management Discussion and Analysis. The SEC indicated that a "critical accounting policy" is one which is both important to the portrayal of a company's financial condition and results, and requires management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our management believes that given current facts and circumstances, there are no material estimates or assumptions with levels of subjectivity and judgement necessary to be considered critical accounting policies.

---

| |
|:---|
| 28 |
| *[**Table of Contents**](#TOC)* |

---

**Off Balance Sheet Arrangements**

We have no off-balance sheet arrangements, including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

Not Applicable.

**Item 4. Controls and Procedures.**

***Disclosure Controls and Procedures***

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2025. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective for the reasons discussed below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of June 30, 2025, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

1. We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management's view that such a committee, including a financial expert member, is an utmost important entity level control over the Company's financial statement. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management's activities.

2. We did not maintain appropriate cash controls – As of June 30, 2025, the Company has not maintained sufficient internal controls over financial reporting for cash, including failure to segregate cash handling and accounting functions, and did not require dual signatures on the Company's bank accounts. 

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company's internal controls.

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

***Changes in Internal Controls over Financial Reporting***

There has been no change in our internal control over financial reporting occurred during the six months ended June 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

---

| |
|:---|
| 29 |
| *[**Table of Contents**](#TOC)* |

---

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

None.

**Item 1A. RISK FACTORS**

Not applicable for smaller reporting companies.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On January 23, 2025, the Company issued 180,000 shares of restricted common stock in settlement of $4,500 of accrued interest.

On January 27, 2025, the Company issued 180,000 shares of restricted common stock in settlement of $4,500 of accrued interest.

**Item 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**Item 4. MINE SAFETY DISCLOSURE**

Not applicable.

**Item 5. OTHER INFORMATION**

(a) None.

(b) During the quarter ending June 30, 2025, there have not been any material changes to the procedures by which security holders may recommend nominees to the Board of Directors.

---

| |
|:---|
| 30 |
| *[**Table of Contents**](#TOC)* |

---

**Item 6. EXHIBITS**

The following documents are filed as part of this report:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [3.1](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex31.htm) | [Articles of Incorporation of Cytta Corp.\*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex31.htm) |
| [3.2](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex32.htm) | [Bylaws of the Company \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex32.htm) |
| [3.3](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex33.htm) | [Amendment to Articles of Incorporation Amending Authorized Common and Preferred Stock \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex33.htm) |
| [3.4](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex34.htm) | [Amended and Restated Certificate of Designation of Series D Preferred Stock \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex34.htm) |
| [3.5](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex35.htm) | [Amended and Restated Certificate of Designation of Series E Preferred Stock \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex35.htm) |
| [3.6](http://www.sec.gov/Archives/edgar/data/1383088/000147793221008813/cyca_ex41.htm) | [Certificate of Designation of Series F Preferred Stock\*\*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221008813/cyca_ex41.htm) |
| [10.1](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex101.htm) | [Agreement by and between Cytta Corp and Makena Investment Advisors, LLC dated April 1, 2020 \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex101.htm) |
| [10.2](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex102.htm) | [Sublease Agreement by and between Cytta Corp and Michael Collins dated October 25, 2020 \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex102.htm) |
| [10.3](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex103.htm) | [Agreement by and between Cytta Corp and Peter Rettman dated August 27, 2020 \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex103.htm) |
| [10.4](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex104.htm) | [Share Issuance agreement by and between Cytta Corp and United Financial Inc., dated September 30, 2020 \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex104.htm) |
| [10.5](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex105.htm) | [Technology Access Agreement by and between Cytta Corp and Michael Collins dated July 19, 2018 \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex105.htm) |
| [14.1](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex141.htm) | [Code of Ethics \*](http://www.sec.gov/Archives/edgar/data/1383088/000147793221004297/cyca_ex141.htm) |
| [31.1](cyca_ex311.htm) | [Certification of Chief Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*\*\*](cyca_ex311.htm) |
| [31.2](cyca_ex312.htm) | [Certification of Chief Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*\*\*](cyca_ex312.htm) |
| [32.1](cyca_ex321.htm) | [Certification of Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63\*\*\*](cyca_ex321.htm) |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).\*\*\* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.\*\*\* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\*\*\* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.\*\*\* |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document.\*\*\* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\*\*\* |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |

---

\* Incorporated by reference to the same exhibit to the registration statement filed by the Company on June 28, 2021.

\*\* Incorporated by reference to exhibit 4.1 to the Current Report on Form 8-K filed by the Company on November 26, 2021.

\*\*\* Filed herewith

---

| |
|:---|
| 31 |
| *[**Table of Contents**](#TOC)* |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: October 30, 2025

---

| |
|:---|
| */s/ Gary Campbell* |
| Gary Campbell |
| Chief Executive Officer |
| (principal executive officer) |
| (principal financial and accounting officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION**

I, Gary Campbell, Chief Executive Officer of CYTTA CORP. (the "registrant"), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the registrant for the period ending June 30, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: October 30, 2025 | By: | */s/ Gary Campbell* |
|  |  | Gary Campbell |
|  |  | Chief Executive Officer |
|  |  | (principal executive officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION**

I, Gary Campbell, Chief Financial Officer of CYTTA CORP. (the "registrant"), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the registrant for the period ending June 30, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: October 30, 2025 | By: | */s/ Gary Campbell* |
|  |  | Gary Campbell |
|  |  | Chief Financial Officer |
|  |  | (principal financial and accounting officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Each of the undersigned hereby certifies, in his capacity as an officer of CYTTA CORP. (the "Company"), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Company's Annual Report on Form 10-Q for the nine months ended June 30, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Dated: October 30, 2025 | By: | */s/ Gary Campbell* |
|  |  | Gary Campbell |
|  |  | Chief Executive Officer |
|  |  | (principal executive officer) |
|  |  | (principal financial and accounting officer) |

---